Japan's Shionogi & Co Ltd (4507.T) said on Wednesday it started a Phase II/III clinical trial for its COVID-19 vaccine candidate.The trial for the recombinant protein-based vaccine will take place in Japan and follows a Phase I trial in the country, Shionogi said in a statement. The
Last year and a half was a big announcement that we need to improve the healthcare infrastructure globally. This pandemic presented us with many areas for innovation and better management, which lead to proactive government policies and participation of businesses and academia alike in R&D.
Per hour, HMD is producing over 4.2 lacs assorted syringes of which 1.4 lacs are A D Syringes
Over 440 million syringes will be supplied by HMD for India’s massive vaccination drive by September of which 365 million were timely supplied till July this year